Brokerages Set Xencor, Inc. (NASDAQ:XNCR) Price Target at $34.38

Shares of Xencor, Inc. (NASDAQ:XNCR) have been assigned an average rating of “Buy” from the eight research firms that are currently covering the company, MarketBeat reports. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $34.38.

A number of equities analysts have recently commented on the company. Wells Fargo & Company cut their price objective on Xencor from $37.00 to $33.00 and set an “overweight” rating on the stock in a report on Friday, February 28th. Piper Sandler raised shares of Xencor from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $20.00 to $30.00 in a research report on Monday, December 2nd. Finally, StockNews.com lowered shares of Xencor from a “hold” rating to a “sell” rating in a research report on Friday, March 14th.

Institutional Investors Weigh In On Xencor

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. GAMMA Investing LLC increased its holdings in Xencor by 31.0% during the 4th quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 508 shares during the last quarter. KBC Group NV grew its position in shares of Xencor by 26.0% during the fourth quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company’s stock worth $90,000 after buying an additional 813 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. grew its position in shares of Xencor by 8.5% during the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 12,156 shares of the biopharmaceutical company’s stock worth $244,000 after buying an additional 949 shares in the last quarter. Sterling Capital Management LLC increased its stake in shares of Xencor by 732.4% in the fourth quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 1,040 shares during the last quarter. Finally, Summit Investment Advisors Inc. raised its holdings in Xencor by 22.2% in the fourth quarter. Summit Investment Advisors Inc. now owns 7,045 shares of the biopharmaceutical company’s stock valued at $162,000 after acquiring an additional 1,282 shares in the last quarter.

Xencor Price Performance

Xencor stock opened at $11.51 on Tuesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23. The company has a market cap of $811.02 million, a price-to-earnings ratio of -3.60 and a beta of 0.74. Xencor has a 1 year low of $10.90 and a 1 year high of $27.24. The firm has a 50 day moving average price of $15.72 and a 200 day moving average price of $20.14.

Xencor (NASDAQ:XNCR) last released its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.62) EPS for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.19. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The business had revenue of $52.79 million during the quarter, compared to the consensus estimate of $17.14 million. Sell-side analysts predict that Xencor will post -3.68 earnings per share for the current year.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.